From these results, we speculated that activation of the MAPK pathway and elevated MCM2 expression may drive the aggressive phenotype of c‐Myc‐positive TNBC, whereas co‐targeting c‐Myc and Ras signalling with Salirasib may suppress tumour progression. Here, MCM2 is linked to neoplasm.